Literature DB >> 31069814

Synthetic testosterone derivatives modulate rat P2X2 and P2X4 receptor channel gating.

Sonja Sivcev1,2, Barbora Slavikova3, Marian Rupert1,4, Milorad Ivetic1, Michaela Nekardova3,5, Eva Kudova3, Hana Zemkova1.   

Abstract

P2X receptors (P2XRs) are ATP-gated cationic channels that are allosterically modulated by numerous compounds, including steroids and neurosteroids. These compounds may both inhibit and potentiate the activity of P2XRs, but sex steroids such as 17β-estradiol or progesterone are reported to be inactive. Here, we tested a hypothesis that testosterone, another sex hormone, modulates activity of P2XRs. We examined actions of native testosterone and a series of testosterone derivatives on the gating of recombinant P2X2R, P2X4R and P2X7R and native channels expressed in pituitary cells and hypothalamic neurons. The 17β-ester derivatives of testosterone rapidly and positively modulate the 1 µM ATP-evoked currents in P2X2R- and P2X4R-expressing cells, but not agonist-evoked currents in P2X7R-expressing cells. In general, most of the tested testosterone derivatives are more potent modulators than endogenous testosterone. The comparison of chemical structures and whole-cell recordings revealed that their interactions with P2XRs depend on the lipophilicity and length of the alkyl chain at position C-17. Pre-treatment with testosterone butyrate or valerate increases the sensitivity of P2X2R and P2X4R to ATP by several fold, reduces the rate of P2X4R desensitization, accelerates resensitization, and enhances ethidium uptake by P2X4R. Native channels are also potentiated by testosterone derivatives, while endogenously expressed GABA receptors type A are inhibited. The effect of ivermectin, a P2X4R-specific allosteric modulator, on deactivation is antagonized by testosterone derivatives in a concentration-dependent manner. Together, our results provide evidence for potentiation of particular subtypes of P2XRs by testosterone derivatives and suggest a potential role of ivermectin binding site for steroid-induced modulation. OPEN SCIENCE BADGES: This article has received a badge for *Open Materials* because it provided all relevant information to reproduce the study in the manuscript. The complete Open Science Disclosure form for this article can be found at the end of the article. More information about the Open Practices badges can be found at https://cos.io/our-services/open-science-badges/.
© 2019 International Society for Neurochemistry.

Entities:  

Keywords:  ATP; P2XR; allosteric modulation; ivermectin; purinergic receptors; testosterone derivatives

Mesh:

Substances:

Year:  2019        PMID: 31069814     DOI: 10.1111/jnc.14718

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  5 in total

1.  P2X4 purinergic receptors offer a therapeutic target for aggressive prostate cancer.

Authors:  Janielle P Maynard; Jiayun Lu; Igor Vidal; Jessica Hicks; Luke Mummert; Tamirat Ali; Ryan Kempski; Ayanna M Carter; Rebecca Y Sosa; Lauren B Peiffer; Corinne E Joshu; Tamara L Lotan; Angelo M De Marzo; Karen S Sfanos
Journal:  J Pathol       Date:  2021-11-25       Impact factor: 7.996

Review 2.  ATP-gated P2X7 receptor as a potential target for prostate cancer.

Authors:  Cuicui Qiao; Yiqing Tang; Qianqian Li; Xiaodi Zhu; Xiaoxiang Peng; Ronglan Zhao
Journal:  Hum Cell       Date:  2022-06-03       Impact factor: 4.374

Review 3.  To Inhibit or Enhance? Is There a Benefit to Positive Allosteric Modulation of P2X Receptors?

Authors:  Leanne Stokes; Stefan Bidula; Lučka Bibič; Elizabeth Allum
Journal:  Front Pharmacol       Date:  2020-05-12       Impact factor: 5.810

Review 4.  Update of P2X receptor properties and their pharmacology: IUPHAR Review 30.

Authors:  Peter Illes; Christa E Müller; Kenneth A Jacobson; Thomas Grutter; Annette Nicke; Samuel J Fountain; Charles Kennedy; Günther Schmalzing; Michael F Jarvis; Stanko S Stojilkovic; Brian F King; Francesco Di Virgilio
Journal:  Br J Pharmacol       Date:  2020-12-21       Impact factor: 9.473

Review 5.  Resolving the Ionotropic P2X4 Receptor Mystery Points Towards a New Therapeutic Target for Cardiovascular Diseases.

Authors:  Bruno Bragança; Paulo Correia-de-Sá
Journal:  Int J Mol Sci       Date:  2020-07-15       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.